Division of Biogen Inc.
Latest From Biogen
Biogen and Eisai still have multiple programs testing amyloid-targeting therapies in the treatment of Alzheimer's disease, but pressure for Biogen to focus its efforts elsewhere are mounting after the partners discontinued Phase III studies for aducanumab.
There have been eight US biopharma IPOs in 2019, but only three are trading above their launch price – a big change from just three days ago.
Novartis and Gilead longer-term data show largely steady response and survival rates, shoring up the clinical and commercial case for their products and justifying continued investment in T-cell therapies. The CAR-T pioneers discuss their progress, including with allogeneic platforms, with Scrip at ASH.
Government seeks dismissal of 10 qui tam complaints related to pharma reimbursement support services, asserting the lawsuits were brought by a ‘professional’ whistleblower and lack merit.
- Therapeutic Areas
- Immune Disorders
- North America
- Parent & Subsidiaries
- Biogen Inc.
- Senior Management
- Contact Info
Phone: (617) 252-9200
14 Cambridge Center
Cambridge, MA 02142
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.